ParkerVision reports Q3 2025 net loss of $2.0M; updates on Qualcomm appeal and upcoming trials

PARKERVISION INC

Net loss $2.0M ($0.02/share) in Q3 2025 vs $10.8M ($0.12/share) in Q3 2024; improvement from lower fair-value loss on contingent payment obligations.
Cash used in ops $4.1M in 9M 2025; cash and equivalents $0.9M at Sep 30, 2025.
CAFC expedites Qualcomm appeal briefing Dec 2025–Feb 2026; Qualcomm moves to dismiss appeal; CAFC not yet ruled.
Patent trials vs Realtek set Jan 12, 2026 and Apr 2026; vs MediaTek set Mar 23, 2026 in Waco, TX.
PTAB decisions on multiple IPRs expected later this month (Nov 2025).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.